Teva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Ethic Inc.

Ethic Inc. raised its position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) by 63.7% in the third quarter, Holdings Channel reports. The fund owned 33,024 shares of the company’s stock after buying an additional 12,853 shares during the quarter. Ethic Inc.’s holdings in Teva Pharmaceutical Industries were worth $1,308,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. WCM Investment Management LLC boosted its stake in Teva Pharmaceutical Industries by 191.4% during the 1st quarter. WCM Investment Management LLC now owns 40,820,600 shares of the company’s stock valued at $1,157,264,000 after purchasing an additional 26,813,522 shares during the period. Wellington Management Group LLP increased its position in Teva Pharmaceutical Industries by 5.8% in the 2nd quarter. Wellington Management Group LLP now owns 7,671,157 shares of the company’s stock worth $259,899,000 after buying an additional 419,329 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Teva Pharmaceutical Industries by 1.5% during the first quarter. Janus Henderson Group PLC now owns 4,816,657 shares of the company’s stock worth $145,076,000 after buying an additional 72,880 shares during the last quarter. Bessemer Group Inc. lifted its holdings in shares of Teva Pharmaceutical Industries by 1.6% during the first quarter. Bessemer Group Inc. now owns 4,350,483 shares of the company’s stock worth $131,036,000 after buying an additional 70,058 shares during the last quarter. Finally, Swiss National Bank grew its stake in shares of Teva Pharmaceutical Industries by 28.7% in the first quarter. Swiss National Bank now owns 4,227,900 shares of the company’s stock worth $127,344,000 after acquiring an additional 941,700 shares during the last quarter. 54.05% of the stock is owned by institutional investors and hedge funds.

More Teva Pharmaceutical Industries News

Investors following TEVA have been watching these news items:

• Positive Sentiment: Piper Sandler raised its price target to $56 from $44 and maintained an Overweight rating, pointing to potential upside. HC Wainwright also issued a positive forecast for Teva’s FY2026 earnings, though the report provided no further details. Piper Sandler analyst rating HC Wainwright forecast
• Positive Sentiment: At its R&D Day, Teva outlined a target of $6–7 billion in innovative-medicines revenue by 2030 and highlighted potential first-in-class pipeline treatments, including for Tourette syndrome, celiac disease and intestinal scarring. These are longer-term opportunities, not guaranteed results. Teva R&D Day announcement
• Negative Sentiment: CEO Richard Francis sold 250,000 shares for about $10.56 million, reducing his direct ownership by 21.23%. EVP Richard Daniell also sold shares in two reported transactions—20,003 shares on Nov. 11 and 25,000 on Nov. 9—cutting his reported stake. Insider selling can weigh on sentiment, although it does not by itself establish the executives’ view of Teva’s prospects. CEO SEC filing EVP SEC filing

Insider Buying and Selling at Teva Pharmaceutical Industries

In related news, CEO Richard Francis sold 250,000 shares of Teva Pharmaceutical Industries stock in a transaction on Tuesday, November 10th. The stock was sold at an average price of $42.24, for a total transaction of $10,560,000.00. Following the completion of the sale, the chief executive officer directly owned 927,529 shares of the company’s stock, valued at $39,178,824.96. The trade was a 21.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Brian Savage sold 7,342 shares of the company’s stock in a transaction dated Friday, September 18th. The shares were sold at an average price of $38.85, for a total value of $285,236.70. Following the completion of the sale, the insider directly owned 8,500 shares of the company’s stock, valued at approximately $330,225. This trade represents a 46.35% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 715,945 shares of company stock valued at $29,061,351 over the last quarter. 0.54% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on TEVA. TD Cowen boosted their target price on shares of Teva Pharmaceutical Industries from $55.00 to $57.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Piper Sandler raised their price target on shares of Teva Pharmaceutical Industries from $44.00 to $56.00 and gave the stock an “overweight” rating in a research report on Thursday. Weiss Ratings upgraded shares of Teva Pharmaceutical Industries from a “hold (c)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th. Oppenheimer boosted their price objective on shares of Teva Pharmaceutical Industries from $50.00 to $52.00 and gave the stock an “outperform” rating in a report on Friday, October 9th. Finally, UBS Group raised their target price on Teva Pharmaceutical Industries from $42.00 to $48.00 and gave the stock a “buy” rating in a research report on Friday, September 4th. Thirteen equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $48.15.

Teva Pharmaceutical Industries Price Performance

Shares of TEVA stock opened at $44.52 on Friday. The firm’s 50 day moving average is $40.16 and its 200-day moving average is $35.07. The firm has a market capitalization of $51.88 billion, a price-to-earnings ratio of 103.53, a PEG ratio of 4.09 and a beta of 0.97. Teva Pharmaceutical Industries Ltd. has a 1 year low of $24.01 and a 1 year high of $44.57. The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 1.59.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its earnings results on Tuesday, November 3rd. The company reported $0.86 earnings per share for the quarter, topping analysts’ consensus estimates of $0.72 by $0.14. Teva Pharmaceutical Industries had a return on equity of 33.20% and a net margin of 2.94%. The company had revenue of $4.39 billion during the quarter, compared to the consensus estimate of $4.23 billion. During the same quarter in the previous year, the company posted $0.78 earnings per share. The firm’s quarterly revenue was down 1.9% on a year-over-year basis. Sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 1.98 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures and markets generic medicines, specialty medicines and biosimilars. Its portfolio spans treatments for conditions including neurological disorders, respiratory diseases and cancer, alongside a broad range of generic medicines across therapeutic areas. Founded in Jerusalem in 1901, Teva has grown from a regional pharmaceutical business into an international company. It serves patients and healthcare providers in markets around the world, including North America, Europe and other regions.